The paper reports on 26 acute, first time or repeatedly diseased schizophrenic
patients, who were treated by Sulpiride in a psychiatric ward. The method used was
a variant of the single-blind technique of administration and evaluation, the basic conception
being that of the ‘neuroleptic threshold’ of Haase. The substance proved to be an
intermediary drug between feeble and middle-potent neuroleptics. In doses about 200 mg/
day, it showed a mood-clearing and stimulating effect. The average dosis necessary to reach
the neuroleptic threshold was 399 mg Sulpiride, the average time being 6 days. An average
dosis of 593.3 mg daily produced in an average time of 11.5 days, dependent from the
initial dose, an evident antipsychotic effect. A good indication for Sulpiride therapy seemed
to be the inhibited and withdrawn patients, but also the restless, highly productive psychoses,
of which 17 from 23 cases showed good results. Extrapyramidal side effects were
not important and could easily be kept under control. Only a certain drowsiness after very
high doses was registered. The indication of Sulpiride in the ambulatory treatment and in
post-psychotic depressions are discussed.
In an open study involving 30 schizophrenic patients the neuroleptic threshold dose (measured via Haase's graphopathological test), the maximum dose, and the maintenance dose were determined. The neuroleptic threshold dose was 5.6 mg/day (0.08 mg/kg body weight); the maximum dose was 11 mg/day (0.16 mg/kg body weight); and the maintenance dose was 6 mg/day (0.09 mg/kg body weight). With reference to the effectiveness, good to very good results were obtained in 19 cases. Regarding side effects 15 patients complained of extrapyramidal disturbances, this was to be expected in view of the study design aiming at the determination of the maximum dose level. When administered in one single dose in the evening, bromperidol influenced the night sleep positively, so that sleep-inducing drugs could be reduced, and, in some cases, even dispensed with.
In an open study involving 30 schizophrenic patients the neuroleptic threshold
dose (measured using Haase’s graphopathological test) and the maximum dose were
determined. The neuroleptic threshold dose was 18.5 mg/day (SD = 8.84), the maximum
dose was 38.2 mg/day (SD = 4.6). With reference to the effectiveness good to very good
results were obtained in 15 cases. Regarding side effects 10 patients complained of extrapyramidal
disturbances. This was to be expected in view of the study design aiming at the
determination of the maximum dose.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.